Oragenics, Inc. announced on May 28, 2025, that its Board of Directors approved a One-for-Thirty (1-for-30) reverse stock split of the company’s issued and outstanding common stock. The reverse stock split was approved on May 27, 2025.
As a result of the reverse stock split, every thirty shares of common stock will be combined into one share. This corporate action is typically undertaken to increase the per-share trading price of a company's stock.
The reverse stock split aims to address compliance with listing requirements or to make the stock more attractive to a broader range of investors. The effective date of the reverse stock split was not immediately specified in this announcement.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.